Business Description
Grace Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : CA00430K4028
Share Class Description:
FRA:L8S: Ordinary SharesDescription
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 632.08 | |||||
| Equity-to-Asset | 0.86 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27.3 | |||||
| 3-Year EPS without NRI Growth Rate | 34.7 | |||||
| 3-Year FCF Growth Rate | 34.2 | |||||
| 3-Year Book Growth Rate | -20 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.48 | |||||
| 9-Day RSI | 68.5 | |||||
| 14-Day RSI | 65.05 | |||||
| 6-1 Month Momentum % | -7.95 | |||||
| 12-1 Month Momentum % | 40.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.01 | |||||
| Quick Ratio | 6.01 | |||||
| Cash Ratio | 5.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.4 | |||||
| Shareholder Yield % | 0.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -18.8 | |||||
| ROA % | -16 | |||||
| ROIC % | -26.49 | |||||
| ROC (Joel Greenblatt) % | -50312.5 | |||||
| ROCE % | -22.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.65 | |||||
| Price-to-Tangible-Book | 5.25 | |||||
| EV-to-EBIT | -0.88 | |||||
| EV-to-EBITDA | -0.88 | |||||
| EV-to-FCF | -1.19 | |||||
| Price-to-Net-Current-Asset-Value | 5.25 | |||||
| Price-to-Net-Cash | 6.04 | |||||
| Earnings Yield (Greenblatt) % | -113.64 | |||||
| FCF Yield % | -32.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Grace Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.186 | ||
| Beta | 0.83 | ||
| Volatility % | 65.92 | ||
| 14-Day RSI | 65.05 | ||
| 14-Day ATR (€) | 0.001658 | ||
| 20-Day SMA (€) | 2.78 | ||
| 12-1 Month Momentum % | 40.4 | ||
| 52-Week Range (€) | 1.89 - 3.14 | ||
| Shares Outstanding (Mil) | 10.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Grace Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Grace Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Grace Therapeutics Inc Frequently Asked Questions
What is Grace Therapeutics Inc(FRA:L8S)'s stock price today?
The current price of FRA:L8S is €2.78. The 52 week high of FRA:L8S is €3.14 and 52 week low is €1.89.
When is next earnings date of Grace Therapeutics Inc(FRA:L8S)?
The next earnings date of Grace Therapeutics Inc(FRA:L8S) is 2025-02-12 Est..
Does Grace Therapeutics Inc(FRA:L8S) pay dividends? If so, how much?
Grace Therapeutics Inc(FRA:L8S) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers